Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
tremfya
Synonyms :
guselkumab
Class :
Anti-psoriatic, monoclonal antibody
Dosage Forms & StrengthsÂ
Injectable solutionÂ
Single-dose prefilled syringeÂ
100mg/mlÂ
Single dose, one-press patient-controlled injectorÂ
100mg/mlÂ
Â
100mg subcutaneous at week 0, week four and every eight weeks
100mg subcutaneous at week 0, week four and every eight weeks
may decrease the therapeutic effect of immunosuppressants
may increase the immunosuppressive effect
may decrease the therapeutic effect of immunosuppressants
may increase the immunosuppressive effect
may decrease the therapeutic effect of immunosuppressants
measles, mumps, rubella, and varicella vaccine, live (Rx)
may decrease the therapeutic effect of immunosuppressants
measles mumps and rubella vaccine, live
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
vaccinia immune globulin intravenous (Rx)
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may increase the immunosuppressive effect
may increase the immunosuppressive effect
may increase the toxic effect of immunosuppressants
may increase the immunosuppressive effect
may increase the toxic effect
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the toxic effect of immunosuppressants
It may enhance the immunosuppressive effects when combined with idecabtagene vicleucel
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect
may increase the immunosuppressive effect of immunosuppressant
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
It may enhance the adverse effects when combined with sotrovimab
Frequency defined:Â Â
>10%Â
Upper respiratory tract infectionsÂ
InfectionsÂ
1-10%Â
Injection site reactionÂ
Herpes simplex infectionsÂ
Elevated liver enzymeÂ
GastroenteritisÂ
HeadacheÂ
ArthralgiaÂ
DiarrheaÂ
Tinea infectionsÂ
Post-marketing reportsÂ
RashÂ
Hypersensitivity reactionsÂ
Pregnancy consideration:Â Â
US FDA Pregnancy category: BÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: guselkumabÂ
Pronounced: (gue sel KOO mab)Â
Why do we use guselkumab?Â
It is used to treat plaque psoriasis and psoriatic arthritis in adults.Â